Another View(s)....

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.

Sabeena Ahmed 1, Mohammad Mahbubul Karim 1, Allen G Ross 1, Mohammad Sharif Hossain 1, John D Clemens 1, Mariya Kibtiya Sumiya 1, Ching Swe Phru 1, Mustafizur Rahman 1, Khalequ Zaman 1, Jyoti Somani 2, Rubina Yasmin 3, Mohammad Abul Hasnat 4, Ahmedul Kabir 5, Asma Binte Aziz 1, Wasif Ali Khan 6
Affiliations expand
• PMID: 33278625

• PMCID: PMC7709596

• DOI: 10.1016/j.ijid.2020.11.191
Free PMC article

Abstract

Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
PubMed Disclaimer

Conflict of interest statement
The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper.

Cumulative viral recovery estimates in…

• Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?
Shukla DAK, Misra DS.Int J Infect Dis. 2021 Aug;109:91. doi: 10.1016/j.ijid.2021.06.048. Epub 2021 Jun 24.PMID: 34175482 Free PMC article. No abstract available.

Similar articles

• Ivermectin for preventing and treating COVID-19.
Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S.Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2.PMID: 34318930 Free PMC article. Updated.

• The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.

Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giráldez M, Mota JS, Yuste JR, Azanza JR, Fernández M, Reina G, Dobaño C, Brew J, Sadaba B, Hammann F, Rabinovich R.Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.PMID: 32513289 Free PMC article.

• Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG.Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.PMID: 33234158 Free PMC article. Clinical Trial.

• Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.
Cobos-Campos R, Apiñaniz A, Parraza N, Cordero J, García S, Orruño E.Curr Res Transl Med. 2021 Oct;69(4):103309. doi: 10.1016/j.retram.2021.103309. Epub 2021 Aug 11.PMID: 34418758 Free PMC article. Review.

• Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
Abegunde AT, Ahuja RM, Okafor NJ.Cochrane Database Syst Rev. 2016 Jan 15;2016(1):CD011146. doi: 10.1002/14651858.CD011146.pub2.PMID: 26771164 Free PMC article. Review.
See all similar articles

• Clinical development of antivirals against SARS-CoV-2 and its variants.
Lan Q, Yan Y, Zhang G, Xia S, Zhou J, Lu L, Jiang S.Curr Res Microb Sci. 2023 Dec 2;6:100208. doi: 10.1016/j.crmicr.2023.100208. eCollection 2024.PMID: 38149085 Free PMC article. Review.

• Synergistic In Vitro Antiviral Effect of Combinations of Ivermectin, Essential Oils, and 18-(Phthalimid-2-yl)ferruginol against Arboviruses and Herpesvirus.
Betancur-Galvis L, Jimenez-Jarava OJ, Rivas F, Mendoza-Hernández WE, González-Cardenete MA.Pharmaceuticals (Basel). 2023 Nov 13;16(11):1602. doi: 10.3390/ph16111602.PMID: 38004467 Free PMC article.

• Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations.
Akter R, Rahman MR, Ahmed ZS, Afrose A.Heliyon. 2023 Jun;9(6):e17478. doi: 10.1016/j.heliyon.2023.e17478. Epub 2023 Jun 21.PMID: 37366526 Free PMC article. Review.

• Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
Wada T, Hibino M, Aono H, Kyoda S, Iwadate Y, Shishido E, Ikeda K, Kinoshita N, Matsuda Y, Otani S, Kameda R, Matoba K, Nonaka M, Maeda M, Kumagai Y, Ako J, Shichiri M, Naoki K, Katagiri M, Takaso M, Iwamura M, Katayama K, Miyatsuka T, Orihashi Y, Yamaoka K; CORVETTE-01 Study Group.Front Med (Lausanne). 2023 May 22;10:1139046. doi: 10.3389/fmed.2023.1139046. eCollection 2023.PMID: 37283627 Free PMC article.

• Ivermectin Effect on In-Hospital Mortality and Need for Respiratory Support in COVID-19 Pneumonia: Propensity Score-Matched Retrospective Study.
Llenas-García J, Del Pozo A, Talaya A, Roig-Sánchez N, Poveda Ruiz N, Devesa García C, Borrajo Brunete E, González Cuello I, Lucas Dato A, Navarro M, Wikman-Jorgensen P.Viruses. 2023 May 10;15(5):1138. doi: 10.3390/v15051138.PMID: 37243224 Free PMC article.

References

1. Alam M.T., Murshed R., Bhiuyan E., Saber S., Alam R., Robin R. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Physic Surg. 2020;38:10–15. doi: 10.3329/jbcps.v38i0.47512. - DOI
2. Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. 2020. "The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, from https://www.ncbi.nlm.nih.gov/pubmed/32251768 (Caly et al. 2020), Apr 3. - PMC - PubMed
3. Centers for Disease Control and Prevention . 2020. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection, Updated March 7, 2020.
4. Chiu S.H., Lu A.Y. In: Ivermectin and Abamectin. Campbell W.C., editor. Springer-Verlag; New York, NY: 1989. Metabolism and tissue residues; pp. 131–143.
5. Johns Hopkins University of Medicine COVID-19 . 2020. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.https://coronavirus.jhu.edu/map.html (accessed 17.11.2020)

More Views...Invitro and Invivo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248252/

Illegitimi non carborundum